Assyro AI

Orange Book product · Brand (NDA)

INVOKAMET

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Brand (NDA)NDA 204353RX JANSSEN PHARMS

At a glance

Aug 08, 2014

Approved

Brand (NDA)

Application

Not listed

TE code

11

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Aug 08, 2014

    12 yr ago

  2. Today

  3. Patent 7943788 expires

    Listed drug substance patent expiration.

    Jul 14, 2027

    in 1 yr 1 mo

  4. Patent 8513202 expires

    Listed drug substance patent expiration.

    Dec 03, 2027

    in 1 yr 6 mo

  5. Patent 8513202 expires

    Listed drug substance patent expiration.

    Dec 03, 2027

    in 1 yr 6 mo

  6. Patent 8513202 expires

    Listed drug substance patent expiration.

    Dec 03, 2027

    in 1 yr 6 mo

  7. Exclusivity ends · NPP

    New patient population exclusivity (3 years)

    Dec 18, 2027

    in 1 yr 6 mo

  8. Patent 7943788*PED expires

    Listed listed patent expiration.

    Jan 14, 2028

    in 1 yr 7 mo

  9. Patent 8513202*PED expires

    Listed listed patent expiration.

    Jun 03, 2028

    in 2 yr

  10. Exclusivity ends · PED

    Pediatric exclusivity (adds 6 months)

    Jun 18, 2028

    in 2 yr

  11. Patent 7943582 expires

    Listed drug substance patent expiration.

    Feb 26, 2029

    in 2 yr 9 mo

  12. Patent 7943582 expires

    Listed drug substance patent expiration.

    Feb 26, 2029

    in 2 yr 9 mo

  13. Patent 7943582 expires

    Listed drug substance patent expiration.

    Feb 26, 2029

    in 2 yr 9 mo

  14. Patent 7943582*PED expires

    Listed listed patent expiration.

    Aug 26, 2029

    in 3 yr 3 mo

  15. Patent 11576894 expires

    Listed drug product patent expiration.

    Jul 06, 2030

    in 4 yr 1 mo

Pharmaceutical detail

Active ingredient

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

Strength

50MG;500MG

Dosage form

TABLET

Route

ORAL

TE code

Not listed

Application

NDA 204353

Product number

001

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Marketing exclusivity (2)

  • NPPNew patient population exclusivity (3 years)

    Dec 18, 2027

    in 1 yr 6 mo

  • PEDPediatric exclusivity (adds 6 months)

    Jun 18, 2028

    in 2 yr

Listed patents (11)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
7943788Jul 14, 2027in 1 yr 1 mo
SubstanceProduct
8513202Dec 03, 2027in 1 yr 6 mo
SubstanceProductU-2441
8513202Dec 03, 2027in 1 yr 6 mo
SubstanceProductU-2632
8513202Dec 03, 2027in 1 yr 6 mo
SubstanceProductU-493
7943788*PEDJan 14, 2028in 1 yr 7 mo
8513202*PEDJun 03, 2028in 2 yr
7943582Feb 26, 2029in 2 yr 9 mo
SubstanceProductU-493
7943582Feb 26, 2029in 2 yr 9 mo
SubstanceProductU-2441
7943582Feb 26, 2029in 2 yr 9 mo
SubstanceProductU-2632
7943582*PEDAug 26, 2029in 3 yr 3 mo
11576894Jul 06, 2030in 4 yr 1 mo
Product
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.